Why track HRT symptoms and response
Starting or adjusting a hormone therapy (HRT) plan isn't a single decision made once and then forgotten — it's something you and your clinician usually revisit over time, adjusting dose, delivery method, or timing based on how your symptoms respond. That review works better with organized data than with memory. Noticing that hot flashes eased within a few weeks, that a symptom hasn't changed six weeks in, or that you missed doses during a specific stretch gives your clinician something concrete to work from at your next appointment, rather than a general impression of "better" or "about the same."
This page isn't about whether to start, stop, or change HRT — that's a decision for you and your clinician, informed by your own health history. It's about keeping the kind of record that makes the follow-up conversation more useful once that decision has already been made.
What to track
The same details that make any symptom easier to discuss apply here, with one addition specific to hormone therapy: timing relative to your regimen.
Frequency. How often is this happening — daily, most days, or a few times a week?
Duration. How long has this specific pattern lasted — since you started treatment, since a dose change, or does it predate HRT entirely?
Severity. On a normal day, is it a mild nuisance or does it stop you doing what you'd otherwise do?
Functional impact. What does it actually change about your day — sleep, concentration, plans you've cancelled?
Timing relative to your regimen. Did a symptom change happen around a dose change, a missed dose, or a delivery-method switch? That kind of timing detail is often the piece a clinician has no way to know unless you log it.
What the research says about individualizing HRT over time
Hormone therapy research is a good illustration of why individual variation, and tracking it, matters. In 2002, a large randomized trial — the Women's Health Initiative — published results suggesting combined hormone therapy increased the risk of breast cancer, stroke, and heart disease in the postmenopausal women studied (Rossouw et al., 2002). Hormone therapy use dropped sharply. But that trial enrolled women across a wide age range, many starting treatment years after menopause began, and a later, more detailed reanalysis by age and time since menopause found a different picture for women who started treatment earlier (Manson et al., 2013).
That distinction is reflected in current guidance: the 2022 position statement from The Menopause Society (published under the organization's former name, NAMS) states that for women under 60 or within 10 years of their final period, the benefit-risk balance for treating symptoms is generally favorable; for women starting later, the calculation is different (The Menopause Society, 2022). The same statement notes that risk also varies by the type, dose, duration, and route of hormone therapy used, and by whether a progestogen is involved — exactly the kind of detail a tracking log, built around your own regimen, can help keep straight over time.
NICE's UK guideline on menopause (NG23, updated November 2024) reflects the same individualized approach in its follow-up structure, recommending that HRT treatment be reviewed around three months after starting, and at least annually after that. A tracking log like the one on this page is meant to give you organized, dated notes to bring to those reviews — not to replace them.
Frequently asked questions
What is the HRT Tracker?
The HRT Tracker is a feature inside the Ripple app for logging your HRT medications, doses, and application sites, then comparing your logged symptom severity from the weeks before and after you started or adjusted a treatment. It's part of Ripple's Premier tier, or available as a standalone HRT add-on.
Is the free tracking log builder on this page the same as the Ripple app's HRT Tracker?
No, and it's worth being clear about the difference. The in-app feature stores your ongoing medication and dose logs, tracks adherence, and computes a before-and-after symptom comparison automatically. This page's builder is simpler: you build one tracking log entry at a time from a fixed checklist, and nothing is saved between visits.
Do I need an account to use the tracking log builder?
No. It works entirely in your browser with no sign-up, no email address, and no popup.
Is my information sent anywhere?
No. Everything you select or type stays in your browser for the current session. Nothing is transmitted to, or stored on, any server — you can verify this yourself by checking your browser's network tab while you use it.
Does this tell me whether to start, stop, or change my HRT?
No. This page and its tracking log builder are for organizing your own observations — they don't recommend starting, stopping, or changing any treatment. That decision is between you and your clinician, informed by your own health history.
Is HRT safe?
This isn't a question with a single yes-or-no answer. A large 2002 trial found real risks in the population it studied; later analysis by age and time since menopause found a more favorable picture for women who start treatment earlier. Current guidance from The Menopause Society reflects that nuance rather than either extreme. Whether hormone therapy is right for you, and how it should be reviewed over time, is a conversation for you and a clinician — not something a page like this can answer.
How often should HRT be reviewed?
NICE's UK guideline on menopause (NG23, updated November 2024) recommends reviewing HRT treatment around three months after starting, and at least annually after that. A tracking log like the one on this page is meant to give you organized, dated notes to bring to those reviews — not to replace them.
Sources
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002;288(3):321–333.
- Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials. JAMA. 2013;310(13):1353–1368.
- The North American Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028. The organisation is now named The Menopause Society.
- NICE guideline NG23, Menopause: identification and management. Published November 2015, updated November 2024. National Institute for Health and Care Excellence.
Related
If you're preparing for an appointment, the free Appointment Prep sheet builder helps you describe symptoms clearly and know what to say if you're not heard. If a symptom hasn't been taken seriously, the free Dismissal Tracker helps you keep a dated record to bring with you. For a structured way to describe your overall symptom severity, try the free Greene Climacteric Scale self-assessment. And if a claim about hormone therapy came up in conversation that you want to check for yourself, see how to read perimenopause and menopause evidence, including a free Evidence Quality Checklist. If you're comparing tracking apps, see Balance app alternative or the Ripple vs Balance feature comparison.